PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 261 filers reported holding PACIRA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.85 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,844 | -73.3% | 46 | -72.8% | 0.00% | -100.0% |
| Q1 2023 | $6,897 | +54.0% | 169 | +45.7% | 0.00% | +100.0% |
| Q4 2022 | $4,479 | -10.4% | 116 | +17.2% | 0.00% | -50.0% |
| Q3 2022 | $5,000 | -37.5% | 99 | -26.7% | 0.00% | 0.0% |
| Q2 2022 | $8,000 | 0.0% | 135 | +25.0% | 0.00% | 0.0% |
| Q1 2022 | $8,000 | -11.1% | 108 | -28.5% | 0.00% | 0.0% |
| Q4 2021 | $9,000 | +28.6% | 151 | +24.8% | 0.00% | 0.0% |
| Q3 2021 | $7,000 | 0.0% | 121 | +3.4% | 0.00% | 0.0% |
| Q2 2021 | $7,000 | -22.2% | 117 | -7.9% | 0.00% | -33.3% |
| Q1 2021 | $9,000 | +12.5% | 127 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $8,000 | +300.0% | 127 | +273.5% | 0.00% | +200.0% |
| Q3 2020 | $2,000 | +100.0% | 34 | +21.4% | 0.00% | – |
| Q2 2020 | $1,000 | – | 28 | +180.0% | 0.00% | – |
| Q1 2020 | $0 | -100.0% | 10 | -79.6% | 0.00% | -100.0% |
| Q4 2019 | $2,000 | -66.7% | 49 | -59.8% | 0.00% | -66.7% |
| Q1 2016 | $6,000 | – | 122 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |